VOVivian Moura de Oliveira

Vivian Moura de Oliveira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vivian Moura de Oliveira has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fructooligosaccharides modulate intestinal fermentation and immune response during Giardia lamblia infection in Meriones unguiculatus

    by Dirce R. DE Oliveira, Michelle B.M.P. Antunes, Vivian M. DE Oliveira, Ruth E. Cruz, Maria A. Gomes

    Giardia lamblia infection alters gut physiology and microbiota interactions, but the impact of prebiotic supplementation in this context remains unclear. This study investigated how fructooligosaccharide (FOS) treatment affects microbial fermentation, intestinal function, inflammation, and hepatic bile acid synthesis in G. lamblia-infected gerbils. Gerbils were divided into four groups: uninfected control, infected control, uninfected and FOS-treated, and infected and FOS-treated. Cecal short-chain fatty acids (SCFAs), intestinal disaccharidase activities, serum and intestinal cytokines, and hepatic expression of Cyp7a1 and Cyp8b1 were analysed. Giardia infection increased cecal acetate, reduced butyrate, elevated serum TNF-α, and increased hepatic Cyp7a1 expression. FOS supplementation increased cecal propionate and other SCFAs and elevated IL-10 levels in serum and intestinal tissue. Notably, FOS reduced intestinal maltase activity regardless of infection status, without affecting lactase activity. Together, these data indicate that giardiasis alters microbial fermentation and inflammatory responses, whereas FOS supplementation primarily promotes a more regulatory immune profile, characterized by increased IL-10 levels, alongside shifts in microbial fermentation, without directly modifying hepatic bile acid–related gene expression. These findings highlight complex diet–microbiota–host interactions during intestinal parasitic infection and support further mechanistic studies.

  • Open Access

    Amebicidal Activity of Escherichia coli Nissle 1917 Against Entamoeba histolytica

    by Vivian Moura-Oliveira, Fabrício M. S. Oliveira, Olga L. M. Moreno, Julia R. Ferreira, Raphael E. Szawka, Ana C. Campideli-Santana, Jullia Teles, Luciano S. A. Capettini, Flaviano S. Martins, Maria A. Gomes

    Amebiasis is a globally prevalent infection that can lead to fatal outcomes if not adequately treated. Conventional treatment with imidazoles often fails due to side effects and resistance, emphasizing the need for alternative therapies. The probiotic Escherichia coli Nissle 1917 (EcN) has shown potential in combating intestinal pathogens. This study aimed to evaluate the amebicidal activity of EcN in vitro and its effect on the production of reactive oxygen species (ROS). Trophozoites of Entamoeba histolytica (2.5 × 10⁴ cells/mL) were cultured in 96-well plates and exposed to varying concentrations of EcN (102–109 cells/mL). Plates were incubated at 36 °C for 6, 12, and 18 h, after which trophozoite viability was assessed. Intracellular ROS production, including superoxide and hydrogen peroxide, was measured using fluorescent probes. The highest efficacy was observed after 18 h at a CFU concentration of 109 cells/mL. Increased ROS production at all probiotic concentrations suggested a role in EcN’s amebicidal mechanism. Morphological changes in trophozoites, such as rounding, vacuolization, and size reduction, were noted after EcN exposure, indicating growth inhibition. These findings suggest EcN induces structural and morphological changes in E. histolytica, inhibiting its growth in vitro. The findings suggest the potential efficacy of EcN; however, definitive confirmation requires data from human clinical trials.

  • Open Access

    Probiotics as a therapeutic alternative in amoebiasis. Where are we?

    by Vivian Moura de Oliveira, Matheus Rezende Corrêa, Isabela Cristina Vieira Silva, Larissa Rezende Corrêa, Maria Aparecida Gomes

    Entamoeba histolytica is the cause of amoebiasis, a neglected tropical disease and a leading cause of mortality worldwide. The objective of this review is to show the potential of probiotics as a treatment strategy for amoebiasis. A systematic search was conducted using PubMed and Google Scholar with keywords "Entamoeba histolytica", "amoebiasis", and "probiotics." The studies on probiotics for amoebiasis treatment are limited, but some shown promising results. Lactobacillus acidophilus reduced E. histolytica cyst excretion by 79.67% in mice, with a 68.31% efficacy comparable to metronidazole. Bifidobacterium sp. showed 75.63% efficacy in reducing infection severity, higher than metronidazole (67.56%). Lactobacillus salivarius inhibited E. histolytica growth in vitro and provided protection in vivo. Lactobacillus fermentum and L. delbrueckii inhibited E. histolytica proliferation with efficacy ranging from 46.42% to 97.68%, depending on the concentration. Saccharomyces boulardii reduced amoebic dysentery duration by 25% and eliminated parasitic cysts in human stool samples. Lactobacillus casei showed a 100% recovery rate in rats infected with E. histolytica. These findings suggest probiotics have potential as therapeutic agents for amoebiasis, but further research is needed to confirm their effectiveness in animal models and humans.